Equibles does not estimate personal net worth.
Get an email with a short summary when Gilead Sciences, Inc. publishes a filing, an earnings call transcript or a press release.
Get GILD alertsAndrew Dickinson is recorded as CFO at Gilead Sciences, Inc. (GILD). The proxy statement of Gilead Sciences, Inc. reports total compensation of $8,765,616 for Andrew Dickinson in fiscal 2025, including a base salary of $1,116,654. Disclosed compensation is on record for 7 fiscal years. Andrew Dickinson has spoken on 25 earnings calls and 4 other investor events across 1 company, most recently for Gilead Sciences, Inc. on August 4, 2026. Gilead Sciences, Inc. is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at Gilead Sciences, Inc. includes Daniel P. O’Day (CEO), Robin L. Washington (CFO), Diane E. Wilfong (Chief Accounting Officer) and 7 others.
“Once again, our quarterly results demonstrated the strength and durability of Gilead's portfolio, underpinned by our disciplined operational execution.”
“We spend a lot of time in China like our peers, and the amount of time that we spend in China has increased over the last five or six years. The quality and depth of assets that we're seeing has improved dramatically even over the last couple of years.”
“As you've heard, Gilead delivered strong first quarter results with continued commercial outperformance and disciplined operating execution.”
“I mean, maybe to start overall, we had an extraordinary 2025 in terms of our base business, our clinical results, the launches. We had two major launches in Yes2Go.”
“I mean, first of all, we think it's an outstanding acquisition for us, for our shareholders. It has a lot of benefits to the company. But first and foremost, we see a much larger commercial opportunity for a neat-o-sell than the market saw.”
Drug Manufacturers - General · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Gilead Sciences, Inc. (GILD) | Chief Financial Officer | $1,116,654 | $8,765,616 |
| 2024 | Gilead Sciences, Inc. (GILD) | Chief Financial Officer | $1,083,969 | $8,109,758 |
| 2023 | Gilead Sciences, Inc. (GILD) | Chief Financial Officer | $1,052,396 | $8,107,823 |
| 2022 | Gilead Sciences, Inc. (GILD) | Chief Financial Officer | $1,018,419 | $8,402,698 |
| 2021 | Gilead Sciences, Inc. (GILD) | Chief Financial Officer | $973,567 | $6,459,795 |
| 2020 | Gilead Sciences, Inc. (GILD) | Chief Financial Officer | $986,538 | $5,841,755 |
| 2019 | Gilead Sciences, Inc. (GILD) | Chief Financial Officer | $802,308 | $5,609,471 |
